BeiGene/BMS Parting Abraxane Ways As China Supply Woes Continue
Competitive Landscape Also Changing
Executive Summary
The latest development over the licensing arrangement for the anticancer drug may deal a further blow to BeiGene’s oncology commercial efforts in China.
You may also be interested in...
China 'No' For Celgene's Paclitaxel A Major Blow To BeiGene
After winning a major procurement contract, BeiGene now may need to find an alternative manufacturing site for Celgene's Abraxane to supply China.
Supply Chain Crunch Meets Olympics Shutdown: China, India Drug Makers Brace For Perfect Storm
To ensure the Beijing Winter Olympics is a smooth affair, the Chinese government has ordered partial or complete halts in industrial production in some provinces from late November until mid-March, disrupting an already fragile global pharma active ingredient supply chain. The emergence of the Omicron coronavirus variant is just adding to the complexities.
BeyondSpring's Next Move Uncertain After Plinabulin CRL
Chinese firm BeyondSpring dealt a setback after the US FDA refuses to approve plinabulin for chemotherapy-induced neutropenia.